

Contents

<i>Contributors</i>	xi
<i>Foreword</i>	xv
<i>Abbreviations</i>	xvii
Chapter 1. Overview of the immune biology of allogeneic hematopoietic stem cell transplantation	1
<i>Gérard Socié and Bruce R Blazar</i>	
Introduction	1
Immune rejection	1
Immune deficiency	4
GVHD pathophysiology	5
The graft-versus-leukemia effect	11
Chapter 2. The HLA system in hematopoietic stem cell transplantation	19
<i>Dominique Charron and Effie Petersdorf</i>	
Introduction	19
Classical HLA	19
The role of classical HLA in unrelated donor hematopoietic cell transplantation	25
The clinical significance of non-classical HLA genes: HLA-E, (HLA-F), HLA-G and MIC genes	29
Conclusions	32
Chapter 3. The impact of minor histocompatibility antigens in allogeneic stem cell transplantation	39
<i>Tuna Mutis and Els Goulmy</i>	
From immunobiology to the impact of mHags in GVHD and GVT	39
Murine mHags, challenges for the human system	40
Immunobiology and biochemical identity of mHags	41
Mechanisms of generation of mHags	41
The impact of individual mHags on GVHD and GVT	42
To match or to mismatch: paradigm shifts in the mHag field	43
Hematopoietic mHags: ideal targets for separating GVT from GVHD	43
Immunotherapeutic targeting of hematopoietic mHags	46
Towards a broad and more effective application of mHag therapy	50
Controlling naturally existing and mHag-specific CD8 ⁺ regulatory T cells	52
Concluding remarks	52

Chapter 4.	<i>In vivo</i> imaging of graft-versus-host disease and graft-versus-leukemia	59
	<i>Dennis B Leveson-Gower and Robert S Negrin</i>	
	Introduction	59
	Bioluminescence imaging	60
	<i>In vivo</i> fluorescence imaging	68
	Nuclear imaging (PET/SPECT)	71
	Magnetic resonance imaging	73
	Multimodal imaging of GVHD and anti-tumor responses	74
	Advances in imaging technology	75
	Conclusion	76
Chapter 5.	Immune rejection: the immune biology of allogeneic hematopoietic stem cell transplantation (from mice to humans)	83
	<i>Paul J Martin and Robert B Levy</i>	
	Introduction	83
	Hematopoietic space and microenvironment	84
	Effector mechanisms of graft rejection	85
	Impact of pretransplant conditioning on effector mechanisms of rejection	92
	Impact of MHC-matching on risk of rejection – from mice to humans	96
	Impact of donor cells on risk of rejection – from mice to humans	97
	Impact of post-transplant immunosuppression on risk of rejection	113
	Future directions	114
Chapter 6.	Strategies to improve post-transplant immunity	123
	<i>Miguel-Angel Perales, Alan M Hanash, Jarrod A Dudakov and Marcel RM van den Brink</i>	
	Introduction	123
	Post-transplant immune deficiency	123
	GVHD of the thymus	125
	Interleukin-7	126
	Keratinocyte growth factor	129
	Sex steroid ablation	130
	Growth hormone	131
	T-cell precursors	131
	Interleukin-22	132
	Flt3L	133
	Other cytokines and growth factors	133
	Conclusions	133
Chapter 7.	Tumor-associated antigens	143
	<i>Gheath Alatrash and Jeffrey J Mollidrem</i>	
	Introduction	143
	Biology of tumor-associated antigens	143
	Aberrantly expressed self-antigens	146
	Tumor-specific antigens	151
	Mutated self-antigens	154
	Cellular approaches to targeting TAA	154
	Unanswered questions	157
	Conclusion	159

Chapter 8.	Impact of the conditioning regimen	165
	<i>E Holler and R Storb</i>	
	First evidence for a role of conditioning in pathophysiology of GVHD	165
	Mechanisms of increased GVHD	166
	Role of inflammation and damage to immunological organs	167
	Controversies and alternative explanations	168
Chapter 9.	Antigen presentation and antigen-presenting cells in graft-versus host-disease	173
	<i>Christian A Wysocki and Warren D Shlomchik</i>	
	Introduction	173
	Major versus minor histocompatibility antigens	175
	Direct versus indirect presentation of miHAs and cross-priming	176
	The roles of host-derived hematopoietic and nonhematopoietic APCs in GVHD	176
	Where does T-cell priming occur?	181
	Priming independent of hematopoietic APCs (revisited)	182
	Specific hematopoietic APC subtypes in GVHD	183
Chapter 10.	T-cell costimulation in graft-versus-host disease and graft-versus-leukemia effect	195
	<i>Xue-Zhong Yu and Claudio Anasetti</i>	
	Introduction	195
	B7/CD28 superfamily	197
	TNF/TNFR superfamily	203
	Regulation of GVHD by costimulation through tregs	209
	Conclusions	214
Chapter 11.	Th1/Th2 and Tc1/Tc2 cells: biology, experimental models, and clinical translation	223
	<i>Daniel H Fowler</i>	
	T-helper differentiation	223
	Experimental transplantation models evaluating the Th1/Th2 paradigm	229
	Clinical transplantation and the Th1/Th2 paradigm	235
	Future directions/unanswered questions	239
Chapter 12.	Natural CD4⁺CD25⁺FOXP3⁺ regulatory T cells in graft-versus-host disease	245
	<i>Matthias Edinger and Petra Hoffmann</i>	
	Introduction	245
	Treg biology	246
	Treg in experimental SCT	252
	Teg in clinical SCT	256
	Summary	262
Chapter 13.	Role of Th17 cells and interleukin 17 in graft-versus-host disease and graft-versus-leukemia reactivity	271
	<i>Xiao Chen and William R Drobyski</i>	
	Discovery of Th17 cells	271
	Differentiation and actions of Th17 cells	272
	Interaction of Th17 cells with Th1, Th2, and Tregs	273
	Role of IL-17 and Th17 cells in preclinical models of acute graft-versus-host disease	274
	Role of IL-17 and Th17 cells in chronic GVHD	278
	Roles of cytokines that induce Th17 differentiation in GVHD	280

Roles of transcription factors involved in Th17 cell differentiation in GVHD	283
Role of IL-17 and Th17 cells in clinical GVHD	284
Role of IL-17 and IL-23R polymorphisms in GVHD	286
Roles of other Th17 cytokines in GVHD biology	288
Role of IL-17 and Th17 cells in GVL reactivity	290
Summary	290
Unanswered questions	291
Acknowledgments	291
Chapter 14. B and T cells in chronic graft-versus-host disease and graft-versus-leukemia	299
<i>Caron A Jacobson and Jerome Ritz</i>	
Introduction	299
Chronic graft-versus-host disease	301
Graft-versus-leukemia and graft-versus-tumor effects of allogeneic transplantation	308
From pathogenesis to therapy: cGVHD and GVL/GVT	311
Conclusions	318
Chapter 15. Natural killer cells in graft-versus-host disease and graft-versus-leukemia	327
<i>Bree Foley, Maite Alvarez, William Murphy and Jeffrey S Miller</i>	
Introduction	327
NK cell receptors	329
NK cell signaling	332
Acquisition of NK cell function	334
NK cell memory	335
Role of NK cells in cancer therapeutics	335
Expanding NK cells	344
Enhancing NK cell function to eliminate tumors	346
The role of NK cells in viral therapy	349
Concluding remarks	350
Chapter 16. Cytokines in graft-versus-host disease and graft-versus-leukemia	357
<i>Kate A Markey, Kelli P A MacDonald and Geoffrey R Hill</i>	
Introduction	357
Stimuli for cytokine production after hematopoietic stem cell transplantation	358
Acute versus chronic GVHD	359
Graft-versus-leukemia effects	360
Critical cytokines in GVHD pathogenesis	360
Cytokines involved in Th1 differentiation	369
Cytokines involved in Th2 differentiation	370
Cytokines involved in Th17/Treg differentiation	372
Cytokines influencing myeloid development and function	377
Summary and conclusions	380
Chapter 17. Chemokines and graft-versus-host disease	393
<i>Kenneth R Cooke, James M Coghil, Gerhard C Hildebrandt and Jonathan S Serody</i>	
Introduction	393
The study of GVHD: A changing paradigm	394
Chemokines and the development of acute GVHD	395
Chemokines and leukocyte trafficking after allogeneic HCT	400

Chemokines and GVT responses	414
Advances in the clinical application of chemokine biology during GVHD	415
Conclusions	418
Acknowledgments	419
Chapter 18. Intracellular sensors of immunity and allogeneic hematopoietic stem cell transplantation	425
<i>Yaping Sun and Pavan Reddy</i>	
Introduction	425
Intracellular sensors	426
Metabolic sensors that regulate allogeneic HSCT	439
Intracellular metabolic changes secondary to immunity	440
Chapter 19. Proteomics in graft-versus-host disease and graft-versus-leukemia	449
<i>Sophie Paczesny</i>	
Definition of biomarkers and pending issues for post-hematopoietic stem cell transplantation clinicians	449
Current proteomics technologies for biomarker discovery	452
Major phases of biomarker development	456
Statistical considerations	457
aGVHD biomarkers: from the identification of candidates to their validation	460
Identification and validation of chronic GVHD biomarkers	468
Identification of GVL and minimal residual disease (MRD) biomarkers	469
Incorporating GVHD biomarkers in clinical trials	471
Future research on biomarkers: from diagnosis to therapy	473
Conclusions	474
Chapter 20. The endothelium in graft-versus-host disease and graft-versus-leukemia	479
<i>Olaf Penack</i>	
The endothelium in graft-versus-host disease	479
Endothelial dysfunction caused by the conditioning regimen	480
Endothelial dysfunction caused by alloreactivity of donor leukocytes	482
Antigen presentation and T-cell activation by endothelial cells during GVHD	483
Neovascularization during GVHD	483
Inhibition of neovascularization during GVHD	484
The endothelium in graft-versus-leukemia	485
Conclusions and perspectives	488
Chapter 21. Looking toward the future: an individualized approach to allogeneic transplantation	493
<i>Craig A Byersdorfer and James L M Ferrara</i>	
An individualized approach to allogeneic transplantation	493
The future of GVHD: diagnosis, prognosis	494
The future of GVHD: treatment	495
Cellular therapy	496
Inhibitors of histone deacetylase	497
Creating platforms for new therapies	498
Prevention and treatment of relapse	499
Novel immunotherapeutics	500
Disease-specific conditioning regimens	500

Cellular therapy for relapse: natural killer cells	500
Maintenance therapy following allogeneic transplantation	501
Improved anti-leukemia effects through T-cell manipulation	501
Conclusion	502

<i>Index</i>	509
--------------	-----